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Abstract 
 
Objective(s) 
The liver has major role in the organism homeostasis, interactions with other systems, synthesis and 
metabolism of bile production, drug detoxification and hormone inactivation. Cholestasis can be defined as 
an impairment of the bile flow which can lead to hepatocytes necrosis and finally cirrhosis. Some studies 
reported a gastric acid secretion reduction in cirrhotic subjects, while others reported normal production 
gastric acid secretion. Our aim was to evaluate the effects of cholestasis and cirrhosis on gastric acid and 
pepsin secretions and its possible mechanism in rat. 
Materials and Methods 
Male Wistar rats were randomly divided into five groups (n= 8): control, cholestasis, sham cholestasis, 
cirrhosis and sham cirrhosis. Laparatomy was done under general anesthesia and then bile duct ligation 
(BDL) was performed. After 2 and 4 weeks in cholestasis and cirrhosis groups respectively, gastric content 
was collected by wash-out technique. Basal and stimulated acid and pepsin secretions were measured by 
using titration and the Anson method respectively in all groups. In order to measure stimulated acid and 
pepsin secretions, pentagastrin (25 µg/kg, i.p.) was used. Nitric Oxide (NO) metabolites of gastric tissue 
were determined by Griess microassy method. 
Results 
Acid and pepsin secretions were significantly reduced in cholestatic and cirrhotic rats in comparison with 
control and sham groups (P< 0.01). NO metabolite of gastric tissue was significantly increased in cholestatic 
and cirrhotic rats (P< 0.01). 
Conclusion 
Reducing of gastric acid and pepsin output in cholestatic and cirrhotic rats may be due to increasing in NO 
content of gastric tissue. 
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Introduction 
The liver plays an important role in the synthesis 
and metabolism of protein, organism 
homeostasis, glucose and bile production, drug 
detoxification and hormone inactivation. 
Therefore, liver diseases, such as cholestasis, can 
deleteriously affect other systems of the body 
(1). Cholestasis can be defined as an impairment 
of the bile flow. The consequences are retention 
of the bile acids, bilirubin and other cholephils in 
the liver and blood. As a result, the release of 
bile acids into the intestine decreases (2). 
Elevated levels of bile acids in the liver can lead 
to apoptosis or necrosis of hepatocytes and 
eventually to cirrhosis (3). Cirrhosis is associated 
with several circulatory abnormalities like 
hyperkinetic circulation (4), gastrointestinal 
bleeding from esophageal varices, ascites, 
hepato-renal syndrome, jaundice, malnutrition 
(5, 6) and severe morphologic changes in the 
intestinal microvilli (7, 8). It also decreases the 
gastrointestinal motility which is demonstrated 
by slowed gastric emptying and prolonged 
gastrointestinal transition time (9, 10). One of the 
most important effects of cirrhosis is the 
increased risk of peptic ulcers (11). The role of 
the cirrhosis in gastric secretion is not well 
known. Some studies reported a reduction in 
acid secretion (12, 13) while others reported 
normal secretion (14-16). The amount of acid 
and  pepsin  secretions  are  also  directly  related       
to peptic ulcer disease. Also, it has been reported 
that N
G –nitro-L-arginine methylester (L-
NAME) has protective effect on gastric damage 
and mucosa secretion in cholestatic rats (17).   
   Therefore, the main goal of this study was to 
evaluate the effects of cholestasis and cirrhosis 
on gastric acid and pepsin secretions, and its 
relation to NO level in the gastric tissue of rat. 
 
Materials and Methods 
The procedures were in accordance with the 
guideline for the care and use of laboratory 
animals of Tehran University of Medical 
Sciences, Tehran, Iran. Male Wistar rats 
weighting 200-250 g were housed in 4 groups, 
maintained in 22±2 °C and 12 hr light/12 hr 
dark cycles and, with free access to food and 
water. The animals were randomly divided 
into five groups (n= 8): control, cholestasis, 
sham cholestasis, cirrhosis and sham cirrhosis. 
Laparatomy was performed under general 
anesthesia (ketamine 50 mg/kg and Xylazine 
10 mg/kg i.p, Gedeon and Alfasan Companies, 
respectively). The common bile duct was 
ligated. After 2 and 4 weeks in cholestasis and 
cirrhosis groups respectively, main experiment 
was done. Before performing experiment, 
animals were deprived of food for 24 hr, but 
had a free access to water. Then under general 
anesthesia (Thiopantal sodium 50 mg/kg, i.p., 
Sandoz Company) tracheotomy and 
laparatomy was performed. After 30 min 
recovery, gastric juice was collected by 
washout technique (The gastric contents were 
removed and 1ml of sample was titrated by 
Titrator (DIN, Germany). After measuring the 
pH, titration was continued up to pH= 7 by 
adding 0.01N sodium hydroxide. Titratable 
acid was calculated and reported as micromole 
acid per 15 min) (18). For measuring basal 
acid output, 1 ml normal saline solution was 
entered in to the stomach, after 15 min another 
1ml was added for dilution and easier 
collection, then stomach content was aspirated 
for acid titration. The remaining gastric juice 
(1 ml) was used for pepsin measurement by 
the Anson method (In this method, pepsin 
acted on the substrate (hemoglobin) and the 
final product of reaction was measured by UV 
spectrophotometer (JENWAY 6105 UV/Vis, 
UK, λ= 280 nm) (18). 
In order to measure pantagastrin-stimulated 
acid  and  pepsin  secretion,  pantagastrin                  
(25  µg/kg,  i.p.  Sigma  Company)  was  used;        
15 min after using of pantagastrin, stimulated 
acid and pepsin secretions were measured (19). 
For omission of circadian rhythms, experiment 
was started at 8 am. Gastric tissue was prepared 
to assay nitric oxide (NO) metabolites by using 
Griess microassy method (20). The animals were 
killed by infusion of potassium chloride to the 
heart at the end of experiments. 
All data are expressed as mean±SEM. 
Statistical analysis of data (NO level in gastric 
tissue, gastric acid and pepsin output) was 
evaluated by means of analysis of variance 
(ANOVA), followed by Tukey’s HSD post 
hoc test. P< 0.05 were considered statistically 
significant.  
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Results 
Plasma bilirubin increased in BDL animal and 
remained significantly higher than control and 
sham groups after the 3
rd  day  of                      
study (control= 137.2±3.2, Sham-cholestasis= 
136.8±3.14, Sham-cirrhosis= 137.5±3.3, 
Cholestasis= 167.5±3.6, cirrhosis= 174.2±3.2 
µmol/lit, P< 0.05) (Figure 1). Two days after 
laparotomy, BDL rats showed manifestations 
of cholestasis (jaundice, dark urine). 
Basal gastric acid secretion was significantly 
decreased in cholestatic and cirrhotic 
(1.82±0.01, 1.47±0.07 µmol/15 min) rats 
compared to the sham cholestasis and sham 
cirrhosis (4.21±0.16, 4.13±0.20 µmol/15 min) 
and control group (4.03±0.12 µmol/15 min) 
(P< 0.01) (Figure 2). Basal gastric acid 
secretions in the cirrhotic (1.47±0.07 µmol/15 
min) group was significantly lower than the 
cholestatic group (1.82±0.01 µmol/15 min) 
(P< 0.05). In comparison with the basal gastric 
acid secretion, the pentagastrin stimulated 
gastric acid secretion showed a significant 
increase in all groups. However, this increase 
in cirrhotic (6.42±0.52 µmol/15 min) and 
cholestatic (7.32±0.56 µmol/15 min) groups 
was milder than the other groups (control= 
11.14±0.98, sham cholestasis= 11.68±0.98, 
sham cirrhosis= 10.73±0.94 µmol/15 min)   
(P< 0.02) (Figure 2).  
  The level of NO metabolites of Gastric tissue 
in cholestatic (69.9±1.70 µm/g/wet.weight) 
and cirrhotic (75.6±1.50 µm/g/wet.weight) 
were significantly higher than the remaining 3 
groups (sham cholestasis=44.20±1.50, sham 
cirrhosis= 45.10±1.60 and control group= 
46.5±1.80 µm/g/wet.weight) (P< 0.01). 
Moreover, this increase in cirrhotic (75.6±1.50 
µm/g/wet.weight) group was significantly 
higher than the cholestatic group (69.9±1.70 
µm/g/wet.weight) (P< 0.05) (Figure 3).  
In the cholestatic and cirrhotic groups, 
(0.35±0.05, 0.21±0.03 µg/15 min respectively) 
there was a significant decrease in basal pepsin 
secretion  compared  to  the  sham  groups         
(sham cholestasis=0.68±0.06, sham cirrhosis=  
0.62±0.04 µg/15 min) and control (0.70±0.07 
µg/15 min) group (P< 0.01) (Figure 4). Basal 
gastric pepsin secretions in the cirrhotic 
(0.21±0.03 µg/15 min) group was significantly 
lower than the cholestatic (0.35±0.05 µg/15 min) 
group (P< 0.05). In comparison with the basal 
gastric pepsin secretion, the pentagastrin 
stimulated gastric pepsin secretion showed a 
significant increase. However, this increase in 
cirrhotic and cholestatic groups (1.08±0.82, 
1.14±0.9 µg/15 min respectively) was lower than 
the other groups (control=2.76±0.24, sham 
cholestasis=2.56±0.12, and sham cirrhosis= 
2.60±0.13 µg/15 min) (P< 0.02) (Figure 4).  
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Figure 1. The level of plasma bilirubin in cholestatic, 
cirrhotic  and  other  groups  (Mean±SEM,  n=  8).          
*P< 0.05 comparison of cholestasis, cirrhosis and 
control, sham-cholestasis and sham-cirrhosis. 
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Figure 2. Comparison of gastric acid secretion in basal 
and stimulated status in 5 groups (Mean±SEM, n=8). 
*P< 0.01 comparison of control, cholestasis & cirrhosis 
in basal acid secretion. 
**P< 0.01 comparison of sham-cholestasis, sham-
cirrhosis and cholestasis & cirrhosis in basal acid 
secretion. 
***P< 0.05 comparison of cholestasis & cirrhosis in 
basal acid secretion.  
+P< 0.02 comparison of control, cholestasis & cirrhosis 
in pentagastrin stimulated acid secretion. 
++P< 0.02 comparison of sham-cholestasis, sham-
cirrhosis and cholestasis & cirrhosis in pentagastrin 
stimulated acid secretion.  
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Figure 3. The level of gastric tissue NO metabolites in 
cholestatic, cirrhotic and other groups (Mean±SEM, 
n=8). 
*P< 0.01 comparison of control, sham-cholestasis, 
sham-cirrhosis, cholestasis & cirrhosis in gastric tissue 
NO metabolite level. 
**P< 0.05 comparison of cholestasis & cirrhosis in 
gastric tissue NO metabolite level. 
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Figure 4. Comparison of gastric pepsin secretion in basal 
and stimulated status in 5 groups (Mean ±SEM, n=8). 
*P< 0.01 comparison of control, cholestasis & cirrhosis 
in basal pepsin secretion. 
**P< 0.01 comparison of sham-cholestasis, sham-
cirrhosis and cholestasis & cirrhosis in basal pepsin 
secretion. 
***P< 0.05 comparison of cholestasis & cirrhosis in 
basal pepsin secretion.
 
+P< 0.02 comparison of control, cholestasis & cirrhosis 
in pentagastrin stimulated pepsin secretion. 
++P< 0.02 comparison of sham-cholestasis, sham-
cirrhosis and cholestasis & cirrhosis in pentagastrin 
stimulated pepsin secretion. 
 
Discussion 
The potent inhibitory effect of cholestasis and 
cirrhosis on acid and pepsin secretions was 
confirmed in the present study. Our results 
showed that cholestasis and cirrhosis can 
increase the levels of gastric tissue NO 
metabolites. However, the mechanism by 
which cholestasis and cirrhosis inhibit acid and 
pepsin secretions is unknown. The role of gastric 
secretion in cirrhosis is controversial; some 
studies reported reduced acid secretion (14, 21) 
while  others  reported  normal  production           
(12, 22). Previous studies showed that secretion 
of gastrin hormone that is itself regulated by 
intragastric pH, regulates the production of HCl 
and pepsin, and finally is partially metabolized 
by the liver and kidneys (23). Basal level of 
serum gastrin is increased in cirrhosis. This 
increase is secondary to gastric hypoacidity and 
decrease of inhibitory feedback of gastrin 
secretion that has an inverse relationship with 
each other (13). It has been found that patients 
suffering from cirrhosis have a gastric pH higher 
than normal and this hypochlorhydria is 
proportional to cirrhosis intensity (24). Studies 
about the 24 hr acidity in cirrhotic patient not 
only showed a marked hypoacidity (25) but also 
a significant decreased of pepsin release (26). 
Neuronal NOS (nNOS) is expressed in parietal 
cells. This finding suggests that endogenous NO, 
acting as an intracellular signaling molecule, 
may participate in the regulation of gastric acid 
secretion. About 50% of the nerves in the enteric 
nervous system contain nNOS (27). It is likely 
that NO inhibits vagally-mediated acid secretion 
by suppressing neuronal activity of the vagus 
nerve (28). Effects of NO on the inhibitory and 
stimulatory actions are complex (29, 30). 
It should be mentioned that NO has dual effect 
on gastric acid secretion, i.e. small amounts of 
NO have a stimulatory effect on gastric ECL 
cells resulting in increased acid secretion, while  
large amounts of NO have an inhibitory effect on 
parietal cells leading to gastric secretion (31, 32).  
 
Conclusion 
It can be concluded that the decrease in acid and 
pepsin secretion in cholestasis & cirrhosis is 
probably the consequence of altered gastric NO 
cellular levels. 
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